Search

Bhagwant D Rege

from Silver Spring, MD
Age ~50
Get Report
Also known as:
Bhagwant Durgadas Rege, Bhagwant D Rage, Durgadas Rege Bhagwant, Rege Bhagwant
Phone and address:
13133 Clifton Rd, Silver Spring, MD 20904
(301) 540-2694
Related to:
Vidyanidhi D RegeDurgadas Rege Bhagwant, 51
Connected to:
Mahesh A Rege, 58Mary Rege, 63Salil U Rege, 50Sonali S Rege, 53Sundeep V Rege, 63Thomas J Rege, 73Vinit U Rege, 42Stanley E Regehr, 89Sydney L Regehr, 81Brian J Regel, 64

Bhagwant Rege Phones & Addresses

  • 13133 Clifton Rd, Silver Spring, MD 20904 (301) 540-2694
  • Germantown, MD
  • Rockville, MD
  • 418 Nottingham Ln, Collegeville, PA 19426
  • 757 Main St, Lansdale, PA 19446
  • Baltimore, MD

Work

Company: Fda Feb 2014 to Jan 2015 Position: Supervisory chemist

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Maryland - Baltimore 1997 to 2001

Skills

Cmc • Drug Development • Pharmaceutical Industry • Formulation • Pharmacokinetics • Hplc • Clinical Development

Ranks

Certificate: Foreign Pharmacy Graduate Equivalency Certification

Industries

Government Administration

Resumes

Resumes

Bhagwant Rege Photo 1

Division Director

View page
Location:
Washington, DC
Industry:
Government Administration
Work:
Fda Feb 2014 - Jan 2015
Supervisory Chemist
Fda Feb 2014 - Jan 2015
Division Director
Fda Sep 2012 - Feb 2014
Cmc Team Leader
Fda Aug 2010 - Sep 2012
Cmc Reviewer
Merck 2004 - Aug 2010
Research Fellow
Education:
University of Maryland - Baltimore 1997 - 2001
Doctorates, Doctor of Philosophy University of Mumbai 1995 - 1997
University of Mumbai 1991 - 1995
Skills:
Cmc
Drug Development
Pharmaceutical Industry
Formulation
Pharmacokinetics
Hplc
Clinical Development
Certifications:
Foreign Pharmacy Graduate Equivalency Certification
Clinical Vaccine Trials and Good Clinical Practice
Building and Leading Effective Teams

Publications

Us Patents

Self-Emulsifying Formulations Of Cetp Inhibitors

View page
US Patent:
8486983, Jul 16, 2013
Filed:
Dec 5, 2006
Appl. No.:
12/085745
Inventors:
Agam R. Sheth - Lansdale PA, US
Bhagwant Rege - Collegeville PA, US
Soumojeet Ghosh - Lansdale PA, US
Laman L. Alani - Lansdale PA, US
Maria T. Cruanes - Lansdale PA, US
Craig A. McKelvey - Ambler PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/421
US Classification:
514376
Abstract:
A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.

Angiotensin Ii Receptor Antagonists

View page
US Patent:
20090123538, May 14, 2009
Filed:
Apr 14, 2006
Appl. No.:
11/886553
Inventors:
Laman L. Alani - Lansdale PA, US
David C. Dubost - Collegeville PA, US
Bruce S. Foster - Scotch Plains NJ, US
Soumojeet Ghosh - Lansdale PA, US
Hossain Jahansouz - North Wales PA, US
Nazaneen Pourkavoos - Ambler PA, US
Bhagwant Rege - Collegeville PA, US
Aditya Tatavarti - Lansdale PA, US
International Classification:
A61K 9/20
C07D 257/04
A61K 31/41
A61P 9/12
A61K 9/16
US Classification:
424464, 548250, 424497, 424494, 514381
Abstract:
The compounds of the present invention are polymorphic crystalline forms of the compound 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, which has the structure (I). Specifically, the compounds of the invention are selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid of Claim selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form I, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form II, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form III, and 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form IV, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form V, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VI, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VII, and 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VIII.

Taste-Masked Tablets And Granules

View page
US Patent:
20090136570, May 28, 2009
Filed:
Jan 16, 2007
Appl. No.:
12/087827
Inventors:
Bhagwant Rege - Collegeville PA, US
Kimberly Kaighn - Glen Mills PA, US
Soumojeet Ghosh - Lansdale PA, US
Laman Alani - Foster City CA, US
International Classification:
A61K 9/20
A61K 31/513
A61K 31/519
A61P 31/18
A61K 31/506
US Classification:
424465, 514269, 5142594, 514215
Abstract:
Orally administered, taste-masked tablets and granules contain (a) a hydroxypyrimidinone carboxamide, a hydroxy-tetrahydropyridopyrimidinone carboxamide, or a related carboxamide compound, or a pharmaceutically acceptable salt thereof, (b) a taste-masking polymer, (c) a superdisintegrant, and optionally other excipients. The carboxamide compound is an HIV integrase inhibitor, and the tablets and granules are suitable for use in the inhibition of HIV integrase, the treatment or prophylaxis of HIV infection, and the treatment or prophylaxis or delay in the onset of AIDS.

Cb-1 Receptor Modulator Formulations

View page
US Patent:
20090264436, Oct 22, 2009
Filed:
Apr 17, 2009
Appl. No.:
12/386402
Inventors:
Craig McKelvey - Ambler PA, US
Sarah Geers - Newark NJ, US
Justin Moser - Collegeville PA, US
Bhagwant Rege - Collegeville PA, US
Dina Zhang - Watchung NJ, US
Sutthilug Sotthivirat - Lansdale PA, US
International Classification:
A61K 31/4985
A61K 31/44
US Classification:
514249, 514351
Abstract:
Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.

Cb-1 Receptor Modulator Formulations

View page
US Patent:
20090264476, Oct 22, 2009
Filed:
Apr 17, 2009
Appl. No.:
12/386403
Inventors:
Craig McKelvey - Ambler PA, US
Sarah Geers - Newark NJ, US
Justin Moser - Collegeville PA, US
Bhagwant Rege - Collegeville PA, US
Dina Zhang - Watchung NJ, US
Sutthilug Sotthivirat - Lansdale PA, US
International Classification:
A61K 31/44
A61K 31/4985
A61P 3/04
US Classification:
514351, 514249
Abstract:
Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabinoid inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.

Formulations For Cathepsin K Inhibitors

View page
US Patent:
20110065800, Mar 17, 2011
Filed:
May 6, 2009
Appl. No.:
12/992124
Inventors:
Haihong Fan - Hatfield PA, US
Majid Mahjour - Schwenksville PA, US
Justin Moser - Collegeville PA, US
Bhagwant Rege - Collegeville PA, US
International Classification:
A61K 31/165
A61P 19/10
A61P 29/00
A61P 19/00
A61P 3/04
A61P 27/06
A61P 35/00
US Classification:
514620
Abstract:
The instant invention relates to pharmaceutical compositions containing cathepsin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions.

Pharmaceutical Compositions Of Combinations Of Dipeptidyl Peptidase-4 Inhibitors With Pioglitazone

View page
US Patent:
20120059011, Mar 8, 2012
Filed:
Jun 4, 2010
Appl. No.:
13/319718
Inventors:
Nicholas Birringer - Philadelphia PA, US
Christopher T. John - Perkiomenville PA, US
Adam Procopio - Cinnaminson NJ, US
Bhagwant Rege - Collegeville PA, US
Lawrence A. Rosen - Wayne PA, US
Sutthilug Sotthivirat - Lansdale PA, US
Wei Xu - North Wales PA, US
International Classification:
A61K 31/4439
A61K 31/513
A61P 3/10
A61K 31/4985
US Classification:
514249, 514342, 514274
Abstract:
This invention relates to pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and pioglitazone, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

Pharmaceutical Compositions Of Combinations Of Dipeptidyl Peptidase-4 Inhibitors With Pioglitazone

View page
US Patent:
20120201885, Aug 9, 2012
Filed:
Oct 12, 2010
Appl. No.:
13/501252
Inventors:
Nicholas Birringer - Philadelphia PA, US
Christopher T. John - Perkiomenville PA, US
Zhen Liu - Chalfont PA, US
Adam Procopio - Cinnaminson NJ, US
Bhagwant Rege - Rockville MD, US
International Classification:
A61K 9/20
A61K 31/675
A61P 3/10
A61K 31/513
A61K 31/4439
A61K 9/28
A61K 31/4985
US Classification:
424465, 424464, 424474, 514 81, 514249, 514274, 514342
Abstract:
This invention relates to a bilayer pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and pioglitazone, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
Control profile
Bhagwant D Rege from Silver Spring, MD, age ~50 Get Report